Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital

BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.

Confident Investing Starts Here:

• Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

• Acadia Pharmaceuticals price target raised to $30 from $27 at Needham

• ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects

• District court finds Aurobindo infringes Acadia Pharmaceuticals patent claims

• Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders

• ACADIA Pharmaceuticals Reports Strong Q1 Earnings Growth